BRAF and melanoma: Similarly, quantitative analysis of tumor associated mutant BRAF extracellular DNA revealed that higher overall response rate to BRAF inhibitors and longer progression free survival were seen in melanoma patients with lower concentration of basal mutant BRAF extracellular DNA [15, 16].